Sumit Sharma, MD, FASRS asks the panel what they are using for first-line AMD treatment and what considerations factor into decision making, such as insurance coverage or risk of inflammation.

EP: 1.Case 1: Treatment-Naïve Neovascular Age-Related Macular Degeneration

Now Viewing

EP: 2.First Line Treatment Decisions for Age-Related Macular Degeneration

EP: 3.Case 2: Diabetic Macular Edema With Severe Vision Loss

EP: 4.MOA and Improved Outcomes: Gaps in Measuring Real-World Results

EP: 5.Case 3: Persistently Active Central Retinal Vein Occlusion

EP: 6.Safety of Advanced Therapies in Clinical Trials vs Real World Experience

EP: 7.Case 4: Neovascular Age-Related Macular Degeneration with Serious Pigment Epithelial Detachment

EP: 8.Final Thoughts on Case Presentations and Advanced Therapies

Related Content

December 4th 2024

Foundation Fighting Blindness joins University of Colorado Anschutz Medical Campus and leading institutions receive funding to fast track whole eye transplantation program

December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

September 26th 2024

Las complejidades en la adopción de una nueva tecnología

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together

November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

May 13th 2024

Study: CRISPR gene editing leads to improvements in vision for people with inherited blindness

May 13th 2024

Researchers: ‘Smart’ contact lenses may one day enable wireless glaucoma detection

Do Not Sell My Personal Information

Job Board

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777